Our Technology
Approach
We offer revolutionary processes that supply safe in vivo cell & gene therapies. For this, we leverage our proprietary EXiVO® approach—an extra-corporeal gene therapy method
EXiVO® Approach
EXiVO® - Extracorporeal in-vivo approach
A new generation of autologous mRNA-T-cell therapeutics designed to revolutionize treatments across indications.
Ex Vivo - In Drug Delivery System: Seamless T-cell hold-step leveraging T-FABfinity® technology, extracorporeal transient modification of selective autologous donor T cells through mRNA-LNP
In Vivo - In Patient: Once returned to the patient, the modified T cells transiently express chimeric antigen receptors (CAR), triggering potent and targeted immune responses within the patient’s body
CELLbricate® ULTRA
Collection of whole blood as starting material
Target cell specific hold step using the T-FABfinity® cell selection column
Genetic modification on or off T-FABfinity® cell selection column (non-viral) via EXiVO approach
In-Process Analytics
Reinfusion of TQx EXiVO cell product
CELLbricate® PRO
Collection of whole blood as starting material
Target cell specific hold step using the T-FABfinity® cell selection column and cell activation FABtivate® agent.
Genetic modification on or off T-FABfinity® cell selection column (viral or non-viral)
In-Process Analytics
Reinfusion of TQx cell product
Advantages of the EXiVO® approach
We are combing the best of two worlds: Ex-vivo cell therapy and in-vivo gene therapy
Safety & Tolerability
Only selected T cells are transfected, ensuring no off-target modifications to other cells in vivo, greatly enhancing patient safety and tolerability
Broad indication applicability
The EXiVO® approach supports various genetic modification methods for both transient & stable integration, allowing to tackle several indications (from autoimmune to oncology), without compromising efficacy or safety
Genetic Modification and In Vivo CAR Expression
Our technology enables transient, controllable CAR expression inside the patient, reducing long-term risks associated with permanent genetic modification
End-to-End Logistics Simplified
The TQx bedside device dramatically reduces supply chain complexity and turnaround time through localized, automated processing, improving clinical efficiency
Cost-Effective
The process uses a single T-cell selection column and minimal volumes of transfection reagents, resulting in significantly lower costs per treatment
Scalable
With processing times under one day, the EXiVO® approach allows for high supply capacity and scalability, meeting increasing clinical demand without compromising quality
You might be interested in
Get in touch!
If you are interested in our technology or platform, feel free to reach out!
TQ Therapeutics GmbH
Fraunhoferstr. 1
82152 Planegg Germany
Phone: +49 89 / 248 870 4 - 50
Email: info@tqtherapeutics.com